The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Primary Immunodeficiency Drug Market Research Report 2025

Global Primary Immunodeficiency Drug Market Research Report 2025

Publishing Date : Mar, 2025

License Type :
 

Report Code : 1790739

No of Pages : 91

Synopsis
Drugs for the treatment of primary immunodeficiency diseases
Global Primary Immunodeficiency Drug market is projected to reach US$ 10690 million in 2029, increasing from US$ 6820 million in 2022, with the CAGR of 6.5% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Primary Immunodeficiency Drug market research.
Based on disease or condition, the antibody deficiency segment held the largest share in the overall PIDD market owing to the increasing number of patients diagnosed with common variable immunodeficiency and selective IgA deficiency. In terms of treatment methods, immunoglobulin replacement therapy occupies the largest share of the global PID market, and is an effective, safe and preferred therapy for the treatment of primary immunodeficiency.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Primary Immunodeficiency Drug market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
ADMA Biologics, Inc.
CSL Behring, LLC
Octapharma
Takeda Pharmaceutical Company
Grifols Biologicals, Inc.
Baxter
Kedrion Biopharma
BPL Inc.
Pharming Group
Shire
Chengdu Rongsheng Pharmaceutical Co., Ltd
Segment by Type
Immunoglobulin
Antibiotic
Stem Cell
Other
Segment by Application
Antibody Deficiency
Cellular Immunodeficiency
Innate Immune Disease
Other
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Primary Immunodeficiency Drug report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Index
1 Primary Immunodeficiency Drug Market Overview
1.1 Product Overview and Scope of Primary Immunodeficiency Drug
1.2 Primary Immunodeficiency Drug Segment by Type
1.2.1 Global Primary Immunodeficiency Drug Market Value Comparison by Type (2023-2029)
1.2.2 Immunoglobulin
1.2.3 Antibiotic
1.2.4 Stem Cell
1.2.5 Other
1.3 Primary Immunodeficiency Drug Segment by Application
1.3.1 Global Primary Immunodeficiency Drug Market Value by Application: (2023-2029)
1.3.2 Antibody Deficiency
1.3.3 Cellular Immunodeficiency
1.3.4 Innate Immune Disease
1.3.5 Other
1.4 Global Primary Immunodeficiency Drug Market Size Estimates and Forecasts
1.4.1 Global Primary Immunodeficiency Drug Revenue 2018-2029
1.4.2 Global Primary Immunodeficiency Drug Sales 2018-2029
1.4.3 Global Primary Immunodeficiency Drug Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Primary Immunodeficiency Drug Market Competition by Manufacturers
2.1 Global Primary Immunodeficiency Drug Sales Market Share by Manufacturers (2018-2023)
2.2 Global Primary Immunodeficiency Drug Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Primary Immunodeficiency Drug Average Price by Manufacturers (2018-2023)
2.4 Global Primary Immunodeficiency Drug Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Primary Immunodeficiency Drug, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Primary Immunodeficiency Drug, Product Type & Application
2.7 Primary Immunodeficiency Drug Market Competitive Situation and Trends
2.7.1 Primary Immunodeficiency Drug Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Primary Immunodeficiency Drug Players Market Share by Revenue
2.7.3 Global Primary Immunodeficiency Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Primary Immunodeficiency Drug Retrospective Market Scenario by Region
3.1 Global Primary Immunodeficiency Drug Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Primary Immunodeficiency Drug Global Primary Immunodeficiency Drug Sales by Region: 2018-2029
3.2.1 Global Primary Immunodeficiency Drug Sales by Region: 2018-2023
3.2.2 Global Primary Immunodeficiency Drug Sales by Region: 2024-2029
3.3 Global Primary Immunodeficiency Drug Global Primary Immunodeficiency Drug Revenue by Region: 2018-2029
3.3.1 Global Primary Immunodeficiency Drug Revenue by Region: 2018-2023
3.3.2 Global Primary Immunodeficiency Drug Revenue by Region: 2024-2029
3.4 North America Primary Immunodeficiency Drug Market Facts & Figures by Country
3.4.1 North America Primary Immunodeficiency Drug Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Primary Immunodeficiency Drug Sales by Country (2018-2029)
3.4.3 North America Primary Immunodeficiency Drug Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Primary Immunodeficiency Drug Market Facts & Figures by Country
3.5.1 Europe Primary Immunodeficiency Drug Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Primary Immunodeficiency Drug Sales by Country (2018-2029)
3.5.3 Europe Primary Immunodeficiency Drug Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Primary Immunodeficiency Drug Market Facts & Figures by Country
3.6.1 Asia Pacific Primary Immunodeficiency Drug Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Primary Immunodeficiency Drug Sales by Country (2018-2029)
3.6.3 Asia Pacific Primary Immunodeficiency Drug Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Primary Immunodeficiency Drug Market Facts & Figures by Country
3.7.1 Latin America Primary Immunodeficiency Drug Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Primary Immunodeficiency Drug Sales by Country (2018-2029)
3.7.3 Latin America Primary Immunodeficiency Drug Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Primary Immunodeficiency Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Primary Immunodeficiency Drug Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Primary Immunodeficiency Drug Sales by Country (2018-2029)
3.8.3 Middle East and Africa Primary Immunodeficiency Drug Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Primary Immunodeficiency Drug Sales by Type (2018-2029)
4.1.1 Global Primary Immunodeficiency Drug Sales by Type (2018-2023)
4.1.2 Global Primary Immunodeficiency Drug Sales by Type (2024-2029)
4.1.3 Global Primary Immunodeficiency Drug Sales Market Share by Type (2018-2029)
4.2 Global Primary Immunodeficiency Drug Revenue by Type (2018-2029)
4.2.1 Global Primary Immunodeficiency Drug Revenue by Type (2018-2023)
4.2.2 Global Primary Immunodeficiency Drug Revenue by Type (2024-2029)
4.2.3 Global Primary Immunodeficiency Drug Revenue Market Share by Type (2018-2029)
4.3 Global Primary Immunodeficiency Drug Price by Type (2018-2029)
5 Segment by Application
5.1 Global Primary Immunodeficiency Drug Sales by Application (2018-2029)
5.1.1 Global Primary Immunodeficiency Drug Sales by Application (2018-2023)
5.1.2 Global Primary Immunodeficiency Drug Sales by Application (2024-2029)
5.1.3 Global Primary Immunodeficiency Drug Sales Market Share by Application (2018-2029)
5.2 Global Primary Immunodeficiency Drug Revenue by Application (2018-2029)
5.2.1 Global Primary Immunodeficiency Drug Revenue by Application (2018-2023)
5.2.2 Global Primary Immunodeficiency Drug Revenue by Application (2024-2029)
5.2.3 Global Primary Immunodeficiency Drug Revenue Market Share by Application (2018-2029)
5.3 Global Primary Immunodeficiency Drug Price by Application (2018-2029)
6 Key Companies Profiled
6.1 ADMA Biologics, Inc.
6.1.1 ADMA Biologics, Inc. Corporation Information
6.1.2 ADMA Biologics, Inc. Description and Business Overview
6.1.3 ADMA Biologics, Inc. Primary Immunodeficiency Drug Sales, Revenue and Gross Margin (2018-2023)
6.1.4 ADMA Biologics, Inc. Primary Immunodeficiency Drug Product Portfolio
6.1.5 ADMA Biologics, Inc. Recent Developments/Updates
6.2 CSL Behring, LLC
6.2.1 CSL Behring, LLC Corporation Information
6.2.2 CSL Behring, LLC Description and Business Overview
6.2.3 CSL Behring, LLC Primary Immunodeficiency Drug Sales, Revenue and Gross Margin (2018-2023)
6.2.4 CSL Behring, LLC Primary Immunodeficiency Drug Product Portfolio
6.2.5 CSL Behring, LLC Recent Developments/Updates
6.3 Octapharma
6.3.1 Octapharma Corporation Information
6.3.2 Octapharma Description and Business Overview
6.3.3 Octapharma Primary Immunodeficiency Drug Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Octapharma Primary Immunodeficiency Drug Product Portfolio
6.3.5 Octapharma Recent Developments/Updates
6.4 Takeda Pharmaceutical Company
6.4.1 Takeda Pharmaceutical Company Corporation Information
6.4.2 Takeda Pharmaceutical Company Description and Business Overview
6.4.3 Takeda Pharmaceutical Company Primary Immunodeficiency Drug Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Takeda Pharmaceutical Company Primary Immunodeficiency Drug Product Portfolio
6.4.5 Takeda Pharmaceutical Company Recent Developments/Updates
6.5 Grifols Biologicals, Inc.
6.5.1 Grifols Biologicals, Inc. Corporation Information
6.5.2 Grifols Biologicals, Inc. Description and Business Overview
6.5.3 Grifols Biologicals, Inc. Primary Immunodeficiency Drug Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Grifols Biologicals, Inc. Primary Immunodeficiency Drug Product Portfolio
6.5.5 Grifols Biologicals, Inc. Recent Developments/Updates
6.6 Baxter
6.6.1 Baxter Corporation Information
6.6.2 Baxter Description and Business Overview
6.6.3 Baxter Primary Immunodeficiency Drug Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Baxter Primary Immunodeficiency Drug Product Portfolio
6.6.5 Baxter Recent Developments/Updates
6.7 Kedrion Biopharma
6.6.1 Kedrion Biopharma Corporation Information
6.6.2 Kedrion Biopharma Description and Business Overview
6.6.3 Kedrion Biopharma Primary Immunodeficiency Drug Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Kedrion Biopharma Primary Immunodeficiency Drug Product Portfolio
6.7.5 Kedrion Biopharma Recent Developments/Updates
6.8 BPL Inc.
6.8.1 BPL Inc. Corporation Information
6.8.2 BPL Inc. Description and Business Overview
6.8.3 BPL Inc. Primary Immunodeficiency Drug Sales, Revenue and Gross Margin (2018-2023)
6.8.4 BPL Inc. Primary Immunodeficiency Drug Product Portfolio
6.8.5 BPL Inc. Recent Developments/Updates
6.9 Pharming Group
6.9.1 Pharming Group Corporation Information
6.9.2 Pharming Group Description and Business Overview
6.9.3 Pharming Group Primary Immunodeficiency Drug Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Pharming Group Primary Immunodeficiency Drug Product Portfolio
6.9.5 Pharming Group Recent Developments/Updates
6.10 Shire
6.10.1 Shire Corporation Information
6.10.2 Shire Description and Business Overview
6.10.3 Shire Primary Immunodeficiency Drug Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Shire Primary Immunodeficiency Drug Product Portfolio
6.10.5 Shire Recent Developments/Updates
6.11 Chengdu Rongsheng Pharmaceutical Co., Ltd
6.11.1 Chengdu Rongsheng Pharmaceutical Co., Ltd Corporation Information
6.11.2 Chengdu Rongsheng Pharmaceutical Co., Ltd Primary Immunodeficiency Drug Description and Business Overview
6.11.3 Chengdu Rongsheng Pharmaceutical Co., Ltd Primary Immunodeficiency Drug Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Chengdu Rongsheng Pharmaceutical Co., Ltd Primary Immunodeficiency Drug Product Portfolio
6.11.5 Chengdu Rongsheng Pharmaceutical Co., Ltd Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Primary Immunodeficiency Drug Industry Chain Analysis
7.2 Primary Immunodeficiency Drug Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Primary Immunodeficiency Drug Production Mode & Process
7.4 Primary Immunodeficiency Drug Sales and Marketing
7.4.1 Primary Immunodeficiency Drug Sales Channels
7.4.2 Primary Immunodeficiency Drug Distributors
7.5 Primary Immunodeficiency Drug Customers
8 Primary Immunodeficiency Drug Market Dynamics
8.1 Primary Immunodeficiency Drug Industry Trends
8.2 Primary Immunodeficiency Drug Market Drivers
8.3 Primary Immunodeficiency Drug Market Challenges
8.4 Primary Immunodeficiency Drug Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Published By : QY Research

Why ‘The Market Reports’